Objective Abacavir, a human immunodeficiency virus-1 (HIV-1) nucleoside-analogue
reverse transcriptase inhibitor, causes severe hypersensitivity in 4–8% of patients. HLA B …

Background Hypersensitivity reaction to abacavir is strongly associated with the presence of
the HLA-B* 5701 allele. This study was designed to establish the effectiveness of …

Abacavir is an effective antiretroviral drug used to treat HIV-1 infection. Approximately 5% of
patients treated with abacavir develop a hypersensitivity reaction that requires …

Abacavir therapy is associated with significant drug hypersensitivity in∼ 8% of recipients,
with retrospective studies indicating a strong genetic association with the HLA-B* 5701 …

Objective: To review the clinical features, risk factors, diagnosis, and management of
abacavir hypersensitivity reaction (HSR). Data Sources: A MEDLINE (1950–October 2007) …

Suspected hypersensitivity is the main reason for the early discontinuation of abacavir. After
the observation that the risk of hypersensitivity correlated with ethnicity, the presence of the …

Abstract Background HLA-B* 57: 01 screening was added to clinical care guidelines in 2008
to reduce the risk of hypersensitivity reaction from abacavir. The uptake of HLA-B* 57: 01 …

Abacavir hypersensitivity syndrome (AHS) is a potentially life-threatening illness occurring in
4–8% of those initiating the drug. Early studies identified a strong association between the …

The introduction of highly active antiretroviral therapy (also known as combination therapy)
has transformed the nature of HIV infection from a severe and ultimately fatal disease to that …

Abacavir is a nucleoside analogue reverse transcriptase inhibitor indicated for the treatment
of human immunodeficiency virus infection as part of a multidrug, highly active antiretroviral …